Engineered Cell Therapies for Metastatic Castrate-Resistant Prostate Cancer – Saul Priceman

At the 29th Annual Prostate Cancer Foundation (PCF) Scientific Retreat Dr Saul Priceman joins Alicia Morgans in a discussion on clinic-ready CAR T cell therapies for Metastatic castrate-resistant prostate cancer (mCRPC) that can overcome the limitations of prior CAR T cell products for prostate cancer. Dr. Priceman highlights the role of PCF’s funds in impacting these research efforts. The…

Read the full article here

Related Articles